MINI-FUTURE LONG - ELI LILLY & CO | Real-time Bid/Ask 10:56:43 2024-07-17 am EDT | ||
| 3.15 CHF / 3.16 CHF | -10.88% |
|
| Current month | +10.28% | ||
| 1 month | +21.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 3.54 | -0.56% |
| 24-07-15 | 3.56 | +2.89% |
| 24-07-12 | 3.46 | +2.67% |
| 24-07-11 | 3.37 | -2.03% |
| 24-07-10 | 3.44 | +3.93% |
Delayed Quote Swiss Exchange
Last update July 16, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYD3U | |
| ISIN | CH1297146479 |
| Date issued | 2023-10-09 |
| Strike | 561.1 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.36 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.56 CHF |
|---|---|
| Lowest since issue | 0.32 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.32% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
901.5
USD
Spread / Average Target
-4.26%
- Stock Market
- Certificates
- LLYD3U Certificat
